Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.32%
-1.76%
-0.19%
+6.18%
+8.63%
Most Trending
+3.32%
-1.76%
-0.19%
+6.18%
+8.63%
Top.GainersTop.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
08 Oct 2025$BURU dominated the gainers with a 37.71% surge to $0.64 on massive volume exceeding 1 billion shares, eight times its average. The industrial blue laser developer caught fire after announcing a defense acquisition and securing global contract wins in after-hours trading Tuesday. The momentum carried through Wednesday as the stock appeared in multiple market headlines alongside major indices. With actual defense contracts materializing rather than just promises, Nuburu is demonstrating real commercial traction, though its penny stock status means volatility will remain elevated.
$ABVE climbed 32.38% to $4.62, marking its seventh consecutive day of gains on volume that exploded to 37.5 million shares versus a typical 2.77 million. The sustained rally without obvious news suggests either systematic accumulation ahead of an announcement or strong technical momentum. Seven-day winning streaks in small caps often precede material news, making this worth monitoring for continuation or profit-taking.
$DGNX jumped 28.06% to $30.99 on its sixth straight day higher, with volume tripling to 1.69 million shares. The biotech's persistent advance without clear catalysts hints at either anticipation of clinical results or partnership news. However, chasing extended runs without fundamental drivers carries significant risk.
$BIAF surged 24.49% to $3.05 after bioAffinity Technologies released its third-quarter sales update. Volume exploded to 34.32 million shares against a 3.93 million average, indicating the quarterly metrics exceeded expectations. The diagnostic commercial traction is resonating with investors despite broader biotech sector challenges.
$RNAZ rounded out the gainers with a 21.11% jump to $14.80 following a Form 8-K filing from Transcode Therapeutics. However, the stock's extremely thin average volume of just 13,040 shares means this news-driven spike could reverse quickly once initial buyers are satisfied.
On the losing side, $COCH crashed 41.5% to $0.93 after Envoy Medical announced a $4 million direct offering with potential for up to $16 million through warrant exercises. The dilutive financing triggered a rush for exits, with volume more than doubling as shareholders fled ahead of the share count expansion.
$ESPR dropped 16.83% to $2.60 after Esperion Therapeutics priced a $75 million stock offering. Volume surged to four times average levels as the cardiovascular biotech's capital raise represented significant dilution that will pressure shares until the market absorbs the new supply.
$NNE fell 16.31% to $47.04 despite announcing a $400 million oversubscribed private placement. NANO Nuclear Energy's decline on positive funding news suggests investor concerns about dilution terms or valuation, with volume tripling normal levels reflecting profit-taking after an extended run.
$DFLI declined 13.49% to $1.25 following the close of its $28.75 million underwritten offering. Dragonfly Energy successfully raised growth capital, but the dilution weighed on sentiment despite the company's promising energy storage technology.
$LXEH slid 17.05% to $0.67, marking its fifth consecutive day of losses without specific news. The sustained selling suggests either technical breakdown or mounting fundamental concerns that haven't yet surfaced publicly.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
